科妍「節膝」關節腔注射劑獲銷售許可,單國內市場還有5倍以上成漫空間,極速娛樂->科妍「節膝」關節腔注射劑獲銷售許可,單國內市場還有5倍以上成漫空間,極速娛樂,極速娛樂
【財訊快報記者何美如報道】玻尿酸廠科妍( 1786 )進軍退化性膝關節炎市場再下一城,「節膝」關節腔注射劑取得衛生福利部(TFDA)核發第三類醫材發賣許可證,此產品添加甘露醇可減緩凝膠分子在皮膚裡的降解速度,為國內獲得的第一張銷售許可證,將推波市占率向上,將來也會延續推動歐盟、東南亞、美國及中國市場。
依據產業查詢拜訪報告,全球關節腔注射劑市場一年約22億美元,年複合成長率近10%,一針劑型更高達30%以上,隨著生齒老化,此類產品每一年需求出現兩位數成長。退化性關節炎人口數在台灣估量近200萬人擺佈,而根據健保局公佈107年關節腔注射劑施打數量推算,國內每一年僅20多萬人次注射關節腔注射劑,市場還有五倍以上之成漫空間。
今朝市道市情上的關節腔注射劑依療程分為五針、三針及一針三種劑型產品,科妍先前首要聚焦在一針、三針產品,海捷特加強型(HYAJOINT Plus)一針劑型關節腔注射劑已在5月取得台灣健保給付核價。
極速娛樂 極速娛樂城
科妍默示,「節膝」關節腔注射劑取得衛生福利部(TFDA)核發第三類醫材發賣許可證,此產品主要用於治療退化性關節,係以「透明質酸」連系「甘露醇」之立異手藝,藉由清除人體自由基,並耽誤透明質酸在關節腔內的珍愛作用,有用晉升原透明質酸產品之功效。
此為國內取得的第一張發賣許可證,估計可提拔國內外關節腔注射劑之需求及市占率,未來將持續鞭策並獲得歐盟、東南亞、中國及美國市場之認證,強化科妍全球之競爭力及營運動能。
原題目:蘋果本年可能會推出10.8英寸iPad,來歲會推出8.5英寸iPad Mini 來曆:新浪科技
蘋果的iPad產品線近年一直在開辟新的尺寸,此刻已經有7.9英寸、9.7英寸、10.2英寸、10.5英寸、11英寸和12.9英寸的iPad產品面世。蘋果的2020新款iPad Pro系列於幾個月前推出,而目下當今,蘋果可能正準備更新iPad和iPad mini系列的型號。根據最新動靜,蘋果企圖推出iPad的兩個新的尺寸版本——本年晚些時候將會推出10.8英寸iPad而且將於2021年推出8.5英寸的iPad Mini。
![](https://imageproxy.pixnet.cc/imgproxy?url=https://newsimgs.sina.tw/article/images/news-15939576959646.jpg)
7bf8-ivrxcex5199193
據MacRumors報導,天風國際分析師郭明錤比來在一份研究陳訴中透露表現,蘋果計劃推出兩種新型號的iPad。10.8英寸機型將庖代現有的10.2英寸機型或10.5英寸iPad Air。而iPad mini將走向8.5英寸,成為該系列的新型號。蘋果客歲3月發佈了第五代iPad mini,比擬前代屏幕尺寸不變,但是內部進行了升級,此中包羅改進的相機和A12處置器和對第一代Apple Pencil的支撐。
除此之外,郭明錤還指出,如之前爆料所表述的一樣,蘋果還將在這兩個新版本的iPad中都附帶20W電源適配器。可是,iPhone 12可能不是這類情形,因為該公司不考慮給iPhone 12標配充電器。而且,耳機也不是標配的一部門。
固然,這些只是臨時的猜想,終究的決定權在於蘋果。不外10.8英寸iPad和8.5英寸iPad Mini的動靜現在越來越多,看起來仿佛很可托,固然,這個10.8英寸iPad到底是屬於iPad第八代還是iPad Air第四代,今朝還不克不及確認。
-->
Privacy policy
This privacy policy sets out how W2D Team uses and protects any information that you give W2D Team when you use this website.
W2D Team is committed to ensuring that your privacy is protected. Should we ask you to provide certain information by which you can be identified when using this website, then you can be assured that it will only be used in accordance with this privacy statement.
W2D Team may change this policy from time to time by updating this page. You should check this page from time to time to ensure that you are happy with any changes.
What we collect:
We may collect the following information:
•name and job title
•contact information including email address
What we do with the information we gather:
We require this information to understand your needs and provide you with a better service, and in particular for the following reasons:
•Internal record keeping.
•We may use the information to improve our products and services.
•We may periodically send promotional emails about new products, special offers or other information which we think you may find interesting using the email address which you have provided.
•From time to time, we may also use your information to contact you for market research purposes. We may contact you by email, phone, fax or mail. We may use the information to customise the website according to your interests.
Security:
We are committed to ensuring that your information is secure. In order to prevent unauthorised access or disclosure, we have put in place suitable physical, electronic and managerial procedures to safeguard and secure the information we collect online.
Links to other websites:
Our website may contain links to other websites of interest. However, once you have used these links to leave our site, you should note that we do not have any control over that other website. Therefore, we cannot be responsible for the protection and privacy of any information which you provide whilst visiting such sites and such sites are not governed by this privacy statement. You should exercise caution and look at the privacy statement applicable to the website in question.
Controlling your personal information:
We will not sell, distribute or lease your personal information to third parties unless we have your permission or are required by law to do so. We may use your personal information to send you promotional information about about Way2Drug news and offers if you tell us that you wish this to happen.
If you believe that any information we are holding on you is incorrect or incomplete, please write to or email us as soon as possible at the above address. We will promptly correct any information found to be incorrect.
來自: https://news.sina.com.tw/article/20200707/35679100.html,https://news.sina.com.tw/article/20200705/35